Gene · 6121
Papers3,325
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,325
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sustained improvement in dark-adapted sensitivity but not BCVA after voretigene neparvovec treatment in a mainland Chinese child with biallelic RPE65-associated LCA2: a case report. | Front Pharmacol | 2026 | 42755963 | PubTator, text mining | PubMed |
| Progress in gene therapy for RPGR-associated X-linked retinitis pigmentosa. | Expert Opin Biol Ther | 2026 | 42733973 | PubTator, text mining | PubMed |
| Delayed foveal atrophy following early visual improvement after voretigene neparvovec gene therapy in a child. | Eye (Lond) | 2026 | 42693233 | PubTator, text mining | PubMed |
| Voretigene Neparvovec (Luxturna) for Biallelic RPE65-Associated Retinal Dystrophy: Systematic Review. | Am J Ophthalmol | 2026 | 42674265 | PubTator, text mining | PubMed |
| Gene therapy clinical trials for inherited eye diseases: The pediatric perspective. | Eur J Ophthalmol | 2026 | 42627399 | PubTator, text mining | PubMed |
| Reverse amblyopia following gene therapy-induced visual improvement in a child with retinal pigment epithelium-65 inherited retinal dystrophy. | BMJ Case Rep | 2026 | 42624634 | PubTator, text mining | PubMed |
| Personalized Pathogenicity Assessment of RPE65 Gene Mutations Using Patient-Specific hiPSC-Derived Retinal Pigment Epithelium Model. | Int J Mol Sci | 2026 | 42449920 | PubTator, text mining | PubMed |
| Congenital stationary night blindness with a fundus albipunctatus-like yellow-dotted retina associated with compound heterozygous RPE65 variants: A case report. | Retin Cases Brief Rep | 2026 | 42447353 | PubTator, text mining | PubMed |
| Post-approval outcomes of voretigene neparvovec (Luxturna®) retinal gene therapy: A systematic review and meta-analysis. | Surv Ophthalmol | 2026 | 42425207 | PubTator, text mining | PubMed |
| Clinical and genetic characteristics of RPE65-associated inherited retinal degeneration in Koreans. | Sci Rep | 2026 | 42365082 | PubTator, text mining | PubMed |
| A Gene Feature Based on Histone Modifications Can Predict the Prognosis of Prostate Cancer. | Biomedicines | 2026 | 42351650 | PubTator, text mining | PubMed |
| Genetic Testing in Inherited Retinal Disease: Current Strategies and Future Directions. | J Pers Med | 2026 | 42346599 | PubTator, text mining | PubMed |
| Clinical Experience with Gene Therapy for Autosomal Recessive RPE65-Related Retinal Dystrophy in the United Arab Emirates. | Ophthalmol Retina | 2026 | 42331100 | PubTator, text mining | PubMed |
| Screening for RPE65 genetic variants in Egyptian children with inherited retinal disorders: a study from a tertiary eye care center in Egypt. | Doc Ophthalmol | 2026 | 42313326 | PubTator, text mining | PubMed |
| Interpreting Hyperreflective Foci in Age-Related Macular Degeneration: A Critical Review of Cell Origins, Evolving Terminology and Clinical Utility. | Clin Exp Ophthalmol | 2026 | 42252770 | PubTator, text mining | PubMed |
| Four-Year Structural and Functional Outcomes of the First Subretinal Voretigene Neparvovec-rzyl Treatment for RPE65-Associated Inherited Retinal Dystrophy in South Korea. | Korean J Ophthalmol | 2026 | 42192584 | PubTator, text mining | PubMed |
| Light-Activated RPE65 Inhibitors Enable On-Demand Visual Cycle Control. | J Am Chem Soc | 2026 | 42156327 | PubTator, text mining | PubMed |
| Voretigene Neparvovec Gene Therapy in Clinical Practice: A 12-Month, Single-Center, In-Depth Analysis of Beneficial and Adverse Drug Effects. | Transl Vis Sci Technol | 2026 | 42117798 | PubTator, text mining | PubMed |
| Gene Therapy Using Recombinant Adeno-Associated Virus for Leber Congenital Amaurosis Induced by RPE65 Mutation. | Clin Ophthalmol | 2026 | 42083640 | PubTator, text mining | PubMed |
| Free-standing chondroitin sulfate/collagen multilayered films as preliminary Bruch's membrane-mimetic platform for retinal pigment epithelial cell culture. | Int J Biol Macromol | 2026 | 42082131 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6121/papers